Pharma continues to be not out of the woods and HDFC Securities has analysed three eventualities to gauge the affect of reciprocal tariffs whereas estimating a success of 3-45% within the EBITDA of home pharmaceutical corporations.
The three eventualities are:
(1) If 100% tariff is borne by Indian pharma corporations, it’ll have a destructive affect of 3-45% on FY27 EBITDA throughout its protection universe. The corporate’s Earnings Earlier than Curiosity, Taxes, Depreciation and Amortisation (EBITDA) is a measure of an organization’s profitability.HDFC Securities in a observe mentioned that Aurobindo Pharma, Dr Reddy’s, Lupin, Solar Pharmaceutical Industries and Zydus Life) would be the worst impacted.
(2) If 50% tariff is to be borne by Indian pharma corporations, it might result in 2-22% affect on FY27E EBITDA, the observe mentioned.
(3) If 35% tariff (1/third of whole tariff) is to be borne by Indian pharma gamers, then a 1-16% hit in FY27E EBITDA is pegged.
Additionally Learn: Gland Pharma, Aurobindo, Lupin, and different pharma shares surge as much as 14% as Trump spares sector from new tariffs
Among the many home corporations, Dr Reddy’s Laboratories and Aurobindo Pharma’s proportion of US gross sales versus their total gross sales, are highest at 46%, every. In USD phrases, that translated to $1,302 million and $1,283 million, respectively in 9MFY25.
Nonetheless, Solar Pharma has the very best US gross sales figures in US greenback phrases at $1,457 million in 9MFY25, HDFC Sec’s brokerage observe mentioned. In share phrases it’s at 31%.
BNP Paribas assumes a ten% tariff is imposed on pharma merchandise and sees a negligible affect on the pharma corporations arguing that the tariff prices might be shared throughout producers, members of the availability chain and the shoppers. It expects a aid rally for the Nifty Pharma Index to proceed after its 11% YTD decline.
HDFC Securities suggestions
— Eris Life: BUY | Goal: 1,500
— IPCA: BUY | Goal: 1,800
— Solar Pharma: BUY | Goal: 1,970
— Alkem: ADD | Goal: 5,700
— Aurobindo: ADD | Goal: 1,350
— Lupin: ADD | Goal: 2,330
— Torrent Pharma: ADD | Goal: 3,640
— Zydus Life: ADD | Goal: 1,120
— Mankind: ADD | Goal: 2,830
— Dr. Reddy’s: REDUCE | Goal: 1,280
(Disclaimer: Suggestions, options, views and opinions given by the specialists are their very own. These don’t signify the views of Financial Instances)
